Advertisement

Erektile Dysfunktion — Ursachen und therapeutische Möglichkeit

  • T. Klotz
Conference paper

Zusammenfassung

In den kommenden 20 Jahren werden in den Industrienationen ca. 30 Prozent aller Einwohner in einem Alter über 60 Jahre sein. Die WHO hat bereits in den 90er-Jahren das „Management“ der Überalterung als eines der vordringlichsten zukünftigen Arbeitsbereiche innerhalb der Industrienationen herausgestellt. Die demografische Entwicklung ist der Auslöser dafür, dass u. a. auch erektile Funktionsstörungen in der Medizin zunehmende Bedeutung erlangen. Erst in den letzten Jahren wurde dieser spezifisch männlichen Erkrankung mehr Aufmerksamkeit geschenkt. Mittlerweile haben sich aufgrund der wissenschaftlichen Erkenntnisse eine urologische Stufendiagnostik und verschiedene Therapiemöglichkeiten etabliert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Becker AJ, Stief CG (2001) Erektile Dysfunktion — Indikationen zur medikamentösen Therapie. Urologe B 41: 122–124CrossRefGoogle Scholar
  2. Boolell M, Allen MJ, Ballard SA et al. (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 8: 47–52Google Scholar
  3. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: Results of the “Cologne Male Survey”. Int J Impôt Res 12: 305–311PubMedCrossRefGoogle Scholar
  4. Braun M, Klotz T, Mathers MJ, Klingebiel J, Zumbe J, Schoenenberger A, Engelmann U (2001) Viagra effect — Influence of mass media on patient behavior. Urol Int 66: 145–148PubMedCrossRefGoogle Scholar
  5. Burnett AL (1995) Role of nitric oxide in the physiology of erection. Biol Reprod 52: 485–489PubMedCrossRefGoogle Scholar
  6. Danjou P, Alexandre L, Warot D et al. (1988) Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Pharmac 26: 733–739CrossRefGoogle Scholar
  7. Ernst E, Pittler MH (1998) Yohimbin for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 159: 433–436PubMedCrossRefGoogle Scholar
  8. Klotz T (2002) Fitness im Alter. Urologe A 41: 315–317PubMedCrossRefGoogle Scholar
  9. Klotz T, Sachse R, Heidrich A et al. (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacokinetic study. World J Urol 19: 32–39PubMedCrossRefGoogle Scholar
  10. Klotz T, Pollock M, Rohde G, Bauer RJ (2002) Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction. Pharmacotherapy 22: 418Google Scholar
  11. Morales A, Gingell C, Collins M, Wicker PA, Osterloh ICH (1998) Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 10: 69–74PubMedCrossRefGoogle Scholar
  12. Moreland RB, Goldstein I, Traish A (1998) Pharmacology letters: Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sciences 62: 309–318CrossRefGoogle Scholar
  13. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH (1996) Triggering myocardial infarction by sexual activity. JAMA 275: 1405–1409PubMedCrossRefGoogle Scholar
  14. Padma-Nathan H, McMurray JG, Rosen RC et al. and the Apomorphine SL study group (1998) Long-term safety and efficacy of Apomorphine SL in patients with male erectile dysfunction. Int J Impotence Res 10[Suppl 3]: 56.Google Scholar
  15. Padma-Nathan H, Auerbach S, Lewis R et al. (1999) Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction. J Urol [Suppl 4]: 214Google Scholar
  16. Paick JS, Lee SW (1994) The neural mechanism of apomorphine-induced erection: an experimental study by comparison with electrostimulation-induced erection in the rat model. J Urol 152: 2125–2128PubMedGoogle Scholar
  17. Porst H (1996) Review article. The rationale for prostaglandin El in erectile failure: A survey of world-wide experience. J Urol 155: 802–815PubMedCrossRefGoogle Scholar
  18. Porst H (2002) Manual der Impotenz. Uni-Med, BremenGoogle Scholar
  19. Rampin O, Bernabe J, Guilano F (1997) Spinal control of penile erection. World J Urol 15: 2–13PubMedCrossRefGoogle Scholar
  20. Saenz de Tejada I (1995) Commentary on mechanisms for the regulation of penile smooth muscle contractility. J Urol 153: 1762CrossRefGoogle Scholar
  21. Sommer F, Klotz T, Steinritz D, Schmidt A, Addicks K, Engelmann U, Bloch W (2002) MAP kinase 1/2 (Erk 1/2) and serin/threonine specific protein kinase Akt/PKB expression and activity in the human corpus cavernosum. Int J Impot Res 14(4): 217–225PubMedCrossRefGoogle Scholar
  22. Telöken C, Rhoden EL, Sogari P et al. (1998) Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 159: 122–124PubMedCrossRefGoogle Scholar
  23. Terret NK, Bell AS, Brown D (1996) Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorganic Med Chemistry Lett 6: 1819–1829CrossRefGoogle Scholar
  24. Vogt HJ, Brandi P, Kockott G (1997) Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of non-organic erectile dysfunction. Int J Impotence Res 9: 155–161CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • T. Klotz

There are no affiliations available

Personalised recommendations